Antiviral Therapy

Papers
(The median citation count of Antiviral Therapy is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-1915
Tenofovir alafenamide fumarate10
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B10
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in p9
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective9
The transformation of HIV therapy: One pill once a day9
Case study of hepatitis C virus control in Egypt: impact of access program9
The curing regimens of HCV: A SWOT analysis7
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir7
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults7
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives6
Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients5
Adefovir for lamivudine-resistant hepatitis B5
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis5
Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study5
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach5
Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey4
Abstracts4
Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor4
Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review4
Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor4
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA4
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients4
Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4+ cell counts4
Impact of new cyclooxygenase 2 inhibitors on human cytomegalovirus replication in vitro4
Discovery and development of oseltamivir at Gilead Sciences4
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study3
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts3
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case3
Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi3
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study3
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)–infected patients3
Oseltamivir and acute hepatitis, reality association or coincidence?3
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis3
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)3
Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV2
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C2
The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study2
Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation2
Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report2
Andrographolide inhibits infectious bronchitis virus-induced apoptosis, pyroptosis, and inflammation2
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers2
The making of the one pill—Developing single tablet regimens for HIV and for HCV2
Real-life findings on the impact of the COVID-19 pandemic on HIV care2
An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide–induced cholestasis2
Subacute thyroiditis following COVID-19 vaccination: Case presentation2
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review2
Topical cidofovir for benign human papillomavirus–associated skin lesions2
Antiviral effect of Artemisia aucheri aqueous extract on UL46 and US6 genes of HSV-12
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting2
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection2
Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report2
Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand2
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants2
The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B2
Virus reactivation in a non-cirrhotic HBV patient requiring liver transplantation after cessation of nucleoside analogue therapy2
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV2
0.014953851699829